Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization.

The objective of these studies was to develop Cremophor-free lipid-based paclitaxel (PX) nanoparticle formulations prepared from warm microemulsion precursors. To identify and optimize new nanoparticles, experimental design was performed combining Taguchi array and sequential simplex optimization. The combination of Taguchi array and sequential simplex optimization efficiently directed the design of paclitaxel nanoparticles. Two optimized paclitaxel nanoparticles (NPs) were obtained: G78 NPs composed of glyceryl tridodecanoate (GT) and polyoxyethylene 20-stearyl ether (Brij 78), and BTM NPs composed of Miglyol 812, Brij 78, and d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Both nanoparticles successfully entrapped paclitaxel at a final concentration of 150 microg/ml (over 6% drug loading) with particle sizes less than 200 nm and over 85% of entrapment efficiency. These novel paclitaxel nanoparticles were stable at 4 degrees C over five months and in PBS at 37 degrees C over 102 h as measured by physical stability. Release of paclitaxel was slow and sustained without initial burst release. Cytotoxicity studies in MDA-MB-231 cancer cells showed that both nanoparticles have similar anticancer activities compared to Taxol. Interestingly, PX BTM nanocapsules could be lyophilized without cryoprotectants. The lyophilized powder comprised only of PX BTM NPs in water could be rapidly rehydrated with a complete retention of original physicochemical properties, in vitro release properties, and cytotoxicity profile. Sequential Simplex Optimization has been utilized to identify promising new lipid-based paclitaxel nanoparticles having useful attributes.

[1]  M. R. Mejillano,et al.  Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. , 1992, Journal of medicinal chemistry.

[2]  A. Driedger,et al.  Review of the toxicologic properties of medium-chain triglycerides. , 2000, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[3]  M. Mattina,et al.  Paclitaxel stability in solution , 1997 .

[4]  C. J. Lee,et al.  Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[5]  R. Mumper,et al.  In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[6]  R. Mumper,et al.  Gadolinium-Loaded Nanoparticles Engineered from Microemulsion Templates , 2002, Drug development and industrial pharmacy.

[7]  S. Guterres,et al.  Freeze-drying polymeric colloidal suspensions: nanocapsules, nanospheres and nanodispersion. A comparative study. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[8]  P. Constantinides,et al.  Formulation Development and Antitumor Activity of a Filter-Sterilizable Emulsion of Paclitaxel , 2000, Pharmaceutical Research.

[9]  Nils-Olof Lindberg,et al.  Multivariate methods in pharmaceutical applications , 2002 .

[10]  B. Leyland-Jones,et al.  Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Westesen,et al.  Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles , 1994 .

[12]  I. Ringel,et al.  Biologically active taxol analogues with deleted A-ring side chain substituents and variable C-2' configurations. , 1991, Journal of medicinal chemistry.

[13]  K. Dimitriadis,et al.  Optimization of the sulforhodamine B colorimetric assay. , 1997, Journal of immunological methods.

[14]  V. Stella,et al.  Degradation of paclitaxel and related compounds in aqueous solutions I: epimerization. , 2008, Journal of pharmaceutical sciences.

[15]  P. Legrand,et al.  Poly(D,L-lactide) nanocapsules prepared by a solvent displacement process: influence of the composition on physicochemical and structural properties. , 2000, Journal of pharmaceutical sciences.

[16]  F M Muggia,et al.  Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  J. Oh,et al.  Blood Compatibility of Cetyl Alcohol/Polysorbate-Based Nanoparticles , 2005, Pharmaceutical Research.

[18]  M. Sznitowska,et al.  Paclitaxel solubility in aqueous dispersions and mixed micellar solutions of lecithin. , 2008, Chemical and pharmaceutical bulletin.

[19]  Chong-Kook Kim,et al.  Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. , 2007, Biomaterials.

[20]  J. Zhang,et al.  Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[21]  M. Gohel,et al.  Formulation optimization of controlled release diclofenac sodium microspheres using factorial design. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[22]  H. Maeda,et al.  Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[23]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Sneddon Sequential simplex optimization , 1992 .

[25]  J. Benoit,et al.  A Novel Phase Inversion-Based Process for the Preparation of Lipid Nanocarriers , 2002, Pharmaceutical Research.

[26]  Wadih Arap,et al.  Probing the structural and molecular diversity of tumor vasculature. , 2002, Trends in molecular medicine.

[27]  H. Fessi,et al.  A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): formulation and process optimization. , 2006, International journal of pharmaceutics.

[28]  V. Venkateswarlu,et al.  Solid lipid nanoparticles as drug delivery systems. , 2005, Methods and findings in experimental and clinical pharmacology.

[29]  S. B. Tiwari,et al.  Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[30]  G. Cavallaro,et al.  Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. , 1996, Biomaterials.

[31]  P. Bummer,et al.  Physical chemical considerations of lipid-based oral drug delivery--solid lipid nanoparticles. , 2004, Critical reviews in therapeutic drug carrier systems.

[32]  Z. Duan,et al.  Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. , 2007, Cancer research.

[33]  Heike Bunjes,et al.  Crystallization tendency and polymorphic transitions in triglyceride nanoparticles , 1996 .

[34]  J. Leroux,et al.  Long circulating lipid nanocapsules for drug detoxification. , 2007, Biomaterials.

[35]  R. Mumper,et al.  Paclitaxel nanoparticles for the potential treatment of brain tumors. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[36]  M. Karlsson,et al.  Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo , 2004, Cancer Chemotherapy and Pharmacology.

[37]  R. Müller,et al.  Nanostructured lipid matrices for improved microencapsulation of drugs. , 2002, International journal of pharmaceutics.

[38]  R. Mumper,et al.  The Metabolism of Fatty Alcohols in Lipid Nanoparticles by Alcohol Dehydrogenase , 2006, Drug development and industrial pharmacy.

[39]  G. Derringer,et al.  Simultaneous Optimization of Several Response Variables , 1980 .

[40]  S. Yuk,et al.  Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. , 2004, International journal of pharmaceutics.